J&J Gains on Claims Its Booster Shot Raises Immunity Against Covid By Investing.com

J&J Gains on Claims Its Booster Shot Raises Immunity Against Covid
© Reuters.

By Dhirendra Tripathi

Investing.com – Johnson & Johnson (NYSE:) stock traded more than 1% up in Tuesday’s premarket on encouraging results from a phase-III real-world study on a booster dose of its Covid-19 vaccine.

The company said its booster shot is 94% effective when administered two months after the first dose. It said the booster increases antibody levels by four to six times relative to one shot.

Boosters given six months after the first shot appear to give even higher protection, the company said. All rises were irrespective of age, the company said.

J&J’s Covid-19 vaccine is the only one approved by western economies that is administered with a single dose.

Around 14.8 million Americans have received the company’s single-dose vaccine so far. The study included 390,000 people who received the J&J Covid-19 vaccine.

An advisory committee on Friday recommended Pfizer (NYSE:) booster shots to people 65 years and older, along with other vulnerable population groups. A final decision from the Food and Drug Administration is expected any day now. The panel voted against endorsing Covid-19 booster shots widely, a plan that the Biden administration favored.

The administration’s plans on boosters have received flak from various quarters, notably the World Health Organization, as much of the world is still unvaccinated, allowing the virus to spread and mutate freely in those countries.


Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All CFDs (stocks, indexes, futures) and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn`t bear any responsibility for any trading losses you might incur as a result of using this data.

Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.

Leave a Reply

Your email address will not be published.